Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VIR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVir Biotechnology expands board to eight, appoints Timothy Coughlin as Audit Chair
Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from seven to eight directors with appointment of Timothy Coughlin, CPA, as Class III director serving through 2028 annual meeting. This is a net addition rather than replacement of departing member.
Item 5.02 verify on EDGAR → -
medium
Coughlin immediately appointed Chair of Audit Committee, bringing CPA credentials to key financial oversight role. Audit Committee oversees financial reporting, internal controls, and external auditor relationships.
Item 5.02 verify on EDGAR → -
low
New director receives standard non-employee compensation including automatic stock option and RSU grants under 2019 Equity Incentive Plan, consistent with existing director pay framework disclosed in 2026 proxy.
Item 5.02 verify on EDGAR →
Summary
Vir Biotechnology expanded its board of directors from seven to eight members on June 9, 2026, appointing Timothy Coughlin as a new Class III director. Coughlin, a CPA, was simultaneously named Chair of the Audit Committee, bringing accounting expertise to the company's financial oversight function.
The appointment represents a board expansion rather than a replacement, suggesting the company is adding capacity rather than responding to a departure. For retail investors, this is a routine governance event with modest positive implications.
Adding an Audit Committee Chair with CPA credentials strengthens financial oversight at a time when biotech companies face intense scrutiny over cash burn rates and clinical trial spending. The expansion to eight directors is within normal range for a public biotech company of Vir's size. Watch for the next quarterly earnings call or proxy statement for additional context on why the board chose to expand now and what specific expertise or connections Coughlin brings beyond his accounting background. Board composition changes sometimes precede strategic shifts, though nothing in this filing suggests immediate operational changes.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Vir Biotechnology appointed Timothy Coughlin as a new Class III director and Audit Committee Chair effective June 9, 2026.
Added in current filing · verify on EDGAR →
the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately
Timothy Coughlin was appointed as Chair of the Audit Committee effective immediately upon joining the Board. This is a key financial oversight role, and his CPA designation suggests relevant expertise for the position.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
As a non-employee director, Mr. Coughlin will receive the standard cash and equity compensation set forth in the Company’s non-employee director compensation policy and described under the caption “Director Compensation” in the Company’s 2026 Proxy Statement, filed with the Securities and Exchange Commission (SEC) on April 16, 2026. Pursuant to the automatic grant program under such policy, on his appointment date, Mr. Coughlin was granted stock option and restricted stock unit awards under the Company’s 2019 Equity Incentive Plan
Mr. Coughlin will receive standard non-employee director compensation including cash and equity awards. He received stock options and restricted stock units upon appointment under the automatic grant program, consistent with the company's existing director compensation framework.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify